Libigel CV benefit potentially 465% bigger then Libigel HSDD and only one safety trial review out of nine remains.
I have not received a response to my e-mail from Scott Henry of Roth Capital. But his 5 star rating will do. I have since sent the same info on the Libigel Connecting the Dots to the other analysts covering Biosante.
Let's see what happens over the next couple of days
Interestingly someone linked to my original post on the Yahoo board under Great Find on ihub and the link. I think most did not realize the info of what was contained in the link and never looked. Interesting to see if the info resurfaces and starts to spread. (Viral would be nice)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.